MedTrace Logo

Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases

NCT00028652 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-12-13

No results posted yet for this study

Summary

RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.

Conditions

Interventions

BIOLOGICAL

interleukin-12 gene

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • David M. Mahvi, MD · University of Wisconsin, Madison

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00028652 on ClinicalTrials.gov